Publication | Open Access

An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer

Metastatic Breast CancerBreast OncologyMedicineImmunologyImmune Checkpoint InhibitorBreast CancerCancer TreatmentImmunotherapyOncologyRadiation OncologyHuman Anti-epcam Antibody